SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (3959)10/20/2015 1:37:06 PM
From: civic08801   of 4474
 
All the more reason that NVS want to both grow and PROTECT their Oncology pipeline in case aria's drug is best in class over their Tasigna..Think about it Very quickly...You can bet that Denner knows where his aria B/O money is going and its likely a company who's stock is way down after the recent meltdown and Denner wants in at a low price like he did with aria,,Joel

Operating from the premise that 600mg Tasigna=15mg Iclusig, one might reason that 150mg Tasigna=no more than 4mg Iclusig. Even if you double the comparison (to 30mg Iclusig), 150mg Tasigna= 8mg Iclusig. Then consider the plasma concentration levels of 6% for Tasigna to 200% Iclusig, that's a factor of apprx. 33X. Even at 1 mg Iclusig, Iclusig is still 4X more present than 150mg Tasigna. 2da's statement on IHUB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News